Autogene Cevumeran + Nivolumab + Saline
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Muscle-invasive Urothelial Carcinoma
Conditions
Muscle-invasive Urothelial Carcinoma
Trial Timeline
Dec 9, 2024 → Jan 6, 2034
NCT ID
NCT06534983About Autogene Cevumeran + Nivolumab + Saline
Autogene Cevumeran + Nivolumab + Saline is a phase 2 stage product being developed by Roche for Muscle-invasive Urothelial Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06534983. Target conditions include Muscle-invasive Urothelial Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06534983 | Phase 2 | Recruiting |
Competing Products
12 competing products in Muscle-invasive Urothelial Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfortumab Vedotin + Pembrolizumab | Astellas Pharma | Phase 2 | 52 |
| Pembrolizumab + Enfortumab Vedotin | Astellas Pharma | Phase 3 | 77 |
| Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG) | AstraZeneca | Phase 3 | 77 |
| Durvalumab (Imfinzi) + Tremelimumab | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab + Gemcitabine | Merck | Phase 2 | 52 |
| Chemotherapy + Immunotherapy Induction + Immunotherapy Maintenance | Merck | Phase 2 | 52 |
| Atezolizumab | Roche | Phase 3 | 77 |
| Nivolumab + Nab-paclitaxel + Nivolumab | Bristol Myers Squibb | Phase 2 | 51 |
| Cretostimogene Grenadenorepvec | CG Oncology | Phase 2 | 49 |
| CG0070 + Nivolumab | CG Oncology | Phase 1 | 30 |
| AU-011 | Aura Biosciences | Phase 1 | 25 |
| REOLYSIN® + Gemcitabine + Cisplatin | Oncolytics Biotech | Phase 1 | 25 |